Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma

Cell Reports

Volumn 3, Issue 2, 2013, Pages 277-281

  Blagoev, Krastan B ^a   Wilkerson, Julia ^b   Stein, Wilfred D ^b,c   Motzer, Robert J ^d   Bates, Susan E ^b   Fojo, A Tito ^b  

^a NATIONAL SCIENCE FOUNDATION   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON DERIVATIVE; SUNITINIB;

ARTICLE; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL PROLIFERATION; HUMANS; INDOLES; INTERFERON-ALPHA; KIDNEY NEOPLASMS; PYRROLES; SURVIVAL ANALYSIS;

ANIMALIA;

EID: 84874254425     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2013.01.015     Document Type: Article

References (15)

1. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
2. Ferrara N. Vascular endothelial growth factor. Arterioscler. Thromb. Vasc. Biol. 2009, 29:789-791.
3. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
4. Folkman J., Merler E., Abernathy C., Williams G. Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med. 1971, 133:275-288.
5. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
6. Heng D.Y., Kollmannsberger C. Sunitinib. Recent Results Cancer Res. 2010, 184:71-82.
7. Kowanetz M., Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin. Cancer Res. 2006, 12:5018-5022.
8. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., Oudard S., Negrier S., Szczylik C., Kim S.T., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007, 356:115-124.
9. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Oudard S., Negrier S., Szczylik C., Pili R., Bjarnason G.A., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2009, 27:3584-3590.
10. Papaetis G.S., Syrigos K.N. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs 2009, 23:377-389.
11. Pàez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Viñals F., Inoue M., Bergers G., Hanahan D., Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
12. Potente M., Gerhardt H., Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011, 146:873-887.
13. Stein W.D., Yang J., Bates S.E., Fojo T. Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. Oncologist 2008, 13:1055-1062.
14. Stein W.D., Wilkerson J., Kim S.T., Huang X., Motzer R.J., Fojo A.T., Bates S.E. Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth. Clin. Cancer Res. 2012, 18:2374-2381.
15. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., Verweij J., Van Glabbeke M., van Oosterom A.T., Christian M.C., Gwyther S.G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000, 92:205-216.